Krystal Biotech (KRYS) Amortization of Deferred Charges (2017)
Krystal Biotech's (KRYS) quarterly Amortization of Deferred Charges came in at $3.2 million in Q3 2017, up 7318.6% quarter-over-quarter from $43000.0 in Q2 2017.
Krystal Biotech (KRYS) Amortization of Deferred Charges (2017) Analysis & Trends
Krystal Biotech has disclosed Amortization of Deferred Charges across 1 years of filings, most recently posting $3.2 million for Q3 2017.
- Amortization of Deferred Charges for Q3 2017 came in at $3.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was $3.3 million (changed N/A YoY), and the FY2017 annual result was $3.3 million, up 46514.29% from the prior year.
- Amortization of Deferred Charges came in at $3.2 million for Q3 2017 at Krystal Biotech, up from $43000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $3.2 million in Q3 2017 to a low of $30000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Krystal Biotech | 10.23 Bn | 9.41 Bn | 110.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 3.19 Mn |
| Sep 30, 2017 | 3.19 Mn |
| Jun 30, 2017 | 43,000.00 |
| Jun 30, 2017 | 43,000.00 |
| Mar 31, 2017 | 30,000.00 |
| Mar 31, 2017 | 30,000.00 |